Skip to main content
. 2021 Aug 31;33(4):470–479. doi: 10.21147/j.issn.1000-9604.2021.04.04

Figure 5.

Figure 5

A comparison of engraftment rates between four phenotypes. (A) Group A, tumors with GPC3 and Ki67; Group B, tumors with GPC3+ and Ki67; Group C, tumors with GPC3 and Ki67+; Group D, tumors with GPC3+ and Ki67+. Subgroups of Ki67 were divided by the cut-off value of nucleus positive rate; (B) Representative phenotypes of PDX in groups A and D; magnification 200×. GPC3, glypican-3; PDX, patient-derived xenograft.